Sarit Assouline
About
Sarit Assouline is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology.
According to data from OpenAlex, Sarit Assouline has authored 164 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Pathology and Forensic Medicine, 80 papers in Genetics and 74 papers in Oncology. Recurrent topics in Sarit Assouline's work include Lymphoma Diagnosis and Treatment (91 papers), Chronic Lymphocytic Leukemia Research (71 papers) and CAR-T cell therapy research (38 papers). Sarit Assouline is often cited by papers focused on Lymphoma Diagnosis and Treatment (91 papers), Chronic Lymphocytic Leukemia Research (71 papers) and CAR-T cell therapy research (38 papers). Sarit Assouline collaborates with scholars based in Canada, United States and United Kingdom. Sarit Assouline's co-authors include Laurie H. Sehn, Matthew J. Matasar, Wilson H. Miller, Elicia Penuel, Caroline Rousseau, Christopher R. Flowers, Alex F. Herrera, Tae Min Kim, Andrew McMillan and Mark Hertzberg and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Sarit Assouline
152 papers receiving 4.4k citations
Hit Papers
Peers
Sarit Assouline
Rebecca Elstrom United States
Alejandro Martı́n Spain
Anna Marina Liberati Italy
Leslie A. Andritsos United States
Sari H. Enschede United States
Laurence Elias United States
Albrecht Reichle Germany
Andrew R. Pettitt United Kingdom
Tahamtan Ahmadi United States
Zijun Y. Xu‐Monette United States
Citations per year, relative to Sarit Assouline Sarit Assouline (= 1×)
peers
Rebecca Elstrom
Countries citing papers authored by Sarit Assouline
Since
Specialization
Citations
This map shows the geographic impact of Sarit Assouline's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarit Assouline with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarit Assouline more than expected).
Fields of papers citing papers by Sarit Assouline
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sarit Assouline. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarit Assouline. The network helps show where Sarit Assouline may publish in the future.
Co-authorship network of co-authors of Sarit Assouline
This figure shows the co-authorship network connecting the top 25 collaborators of Sarit Assouline. A scholar is included among the top collaborators of Sarit Assouline based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarit Assouline. Sarit Assouline is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Tucci, Alessandra, Yair Herishanu, Sarit Assouline, et al.. (2025). Phase 2 bellwave-003 cohort f: Updated clinical outcomes of nemtabrutinib in participants with relapsed or refractory marginal zone lymphoma. Blood. 146(Supplement 1). 1801–1801.
2.
Bartlett, Nancy L., Laurie H. Sehn, Sarit Assouline, et al.. (2024). Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II. Blood. 144(Supplement 1). 1645–1645.
3.
Budde, Lihua E., Sarit Assouline, Laurie H. Sehn, et al.. (2024). Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of Clinical Oncology. 42(19). 2250–2256.
4.
Deschênes‐Simard, Xavier, Frédéric Barabé, Vinçent Laroche, et al.. (2024). Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study. Leukemia & lymphoma. 65(13). 1974–1982.
5.
Assouline, Sarit, Lihua E. Budde, Julio C. Chávez, et al.. (2024). Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7021–7021.
6.
Budde, Lihua E., Matthew J. Matasar, Laurie H. Sehn, et al.. (2024). Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma. Blood. 144(Supplement 1). 1646–1646.
7.
Assouline, Sarit, Lihua E. Budde, Julio C. Chávez, et al.. (2024). Mosunetuzumab With Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL). Clinical Lymphoma Myeloma & Leukemia. 24. S212–S212.
8.
Ravandi‐Kashani, Farhad, Aaron D. Goldberg, Elie Traer, et al.. (2023). PHASE 1 STUDY OF PRT1419 (MCL1 INHIBITOR) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MYELOID OR B‐CELL MALIGNANCIES. Hematological Oncology. 41(S2). 834–835.
9.
Matasar, Matthew J., Nancy L. Bartlett, Mazyar Shadman, et al.. (2023). Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. Clinical Lymphoma Myeloma & Leukemia. 24(4). 240–253.
10.
Kater, Arnon P., Rosemary Harrup, Thomas J. Kipps, et al.. (2023). MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Hematological Oncology. 41(S2). 239–242.
11.
Schuster, Stephen J., Ling‐Yuh Huw, Christopher R. Bolen, et al.. (2023). Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas. Blood. 143(9). 822–832.
12.
Sehn, Laurie H., Mark Hertzberg, Stephen Opat, et al.. (2021). Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Advances. 6(2). 533–543.
13.
Assouline, Sarit, Amitkumar Mehta, Tycel Phillips, et al.. (2021). TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data. Blood. 138(Supplement 1). 2488–2488.
14.
Mistry, Pramod K., Elena Lukina, Hadhami Ben Turkia, et al.. (2021). Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results. American Journal of Hematology. 96(9). 1156–1165.
15.
Matasar, Matthew J., Chan Y. Cheah, Dok Hyun Yoon, et al.. (2020). Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. Blood. 136(Supplement 1). 45–46.
16.
Assouline, Sarit, Lilian Amrein, Raquel Aloyz, et al.. (2020). IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 61(7). 1653–1659.
17.
Ruskey, Jennifer A., Sirui Zhou, Raoul Santiago, et al.. (2018). The GBA p.Trp378Gly mutation is a probable French‐Canadian founder mutation causing Gaucher disease and synucleinopathies. Clinical Genetics. 94(3-4). 339–345.
18.
Budde, Lihua E., Laurie H. Sehn, Sarit Assouline, et al.. (2018). Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study. Blood. 132(Supplement 1). 399–399.
19.
Klil‐Drori, Adi J., Hui Yin, Laurent Azoulay, et al.. (2017). Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study. Blood. 130. 315–315.
20.
Assouline, Sarit, Marie‐Pierre Sylvestre, Philippe Carrière, Chaim Shustik, & Pierre Laneuville. (2005). Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high‐dose cyclophosphamide: a retrospective review of 141 patients. Transfusion. 46(2). 174–179.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Rebecca Elstrom Breakdown of academic impact, for papers by Alejandro Martı́n Breakdown of academic impact, for papers by Anna Marina Liberati Breakdown of academic impact, for papers by Leslie A. Andritsos Breakdown of academic impact, for papers by Sari H. Enschede Breakdown of academic impact, for papers by Laurence Elias Breakdown of academic impact, for papers by Albrecht Reichle Breakdown of academic impact, for papers by Andrew R. Pettitt Breakdown of academic impact, for papers by Tahamtan Ahmadi Breakdown of academic impact, for papers by Zijun Y. Xu‐Monette